<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35908724</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Persistent symptoms, quality of life, and risk factors in long COVID: a cross-sectional study of hospitalized patients in Brazil.</ArticleTitle><Pagination><StartPage>1044</StartPage><EndPage>1051</EndPage><MedlinePgn>1044-1051</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2022.07.063</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(22)00458-1</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">COVID-19 has been associated with long-term consequences to patient wellness and quality of life. Data on post-COVID-19 conditions are scarce in developing countries. This study aimed to investigate long COVID in a cohort of hospitalized patients in Brazil.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Surviving patients discharged from the hospital between July 1, 2020 and March 31, 2021 were assessed between 2 and 12 months after acute onset of COVID-19. The outcomes were the prevalence of persistent symptoms, risk factors associated with long COVID, and quality of life as assessed by the EuroQol 5D-3L questionnaire.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 439 participants, most (84%) reported at least one long COVID symptom, at a median of 138 days (interquartile range [IQR] 90-201) after disease onset. Fatigue (63.1%), dyspnea (53.7%), arthralgia (56.1%), and depression/anxiety (55.1%) were the most prevalent symptoms. In multivariate analysis, dysgeusia (odds ratio [OR] 2.0, 95% confidence interval [CI] 1.18-3.44, P &lt;0.001) and intensive care unit (ICU) admission (OR 2.6, 95% CI 1.19-6.56, P = 0.03) were independently associated with long COVID. Fifty percent of patients reported a worsened clinical condition and quality of life.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Long-term outcomes of SARS-CoV-2 infection in a low- to middle-income country were relevant. Fatigue was the most common persistent symptom. ICU admission was an independent factor associated with long COVID. Dysgeusia could be a potential predictor of long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Oliveira</LastName><ForeName>Jacqueline Ferreira</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Infectious Disease Division, Eduardo de Menezes Hospital, Funda&#xe7;&#xe3;o Hospitalar do Estado de Minas Gerais, Belo Horizonte, Brazil. Electronic address: jacfoliveira@yahoo.com.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de &#xc1;vila</LastName><ForeName>Renata Eliane</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Infectious Disease Division, Eduardo de Menezes Hospital, Funda&#xe7;&#xe3;o Hospitalar do Estado de Minas Gerais, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Oliveira</LastName><ForeName>Neimy Ramos</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Critical Care Unit, Eduardo de Menezes Hospital, Funda&#xe7;&#xe3;o Hospitalar do Estado de Minas Gerais, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Cunha Severino Sampaio</LastName><ForeName>Nat&#xe1;lia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Critical Care Unit, Eduardo de Menezes Hospital, Funda&#xe7;&#xe3;o Hospitalar do Estado de Minas Gerais, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botelho</LastName><ForeName>Maiara</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Epidemiology Division, Eduardo de Menezes Hospital, Funda&#xe7;&#xe3;o Hospitalar do Estado de Minas Gerais, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gon&#xe7;alves</LastName><ForeName>Fab&#xed;ola Ara&#xfa;jo</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Epidemiology Division, Eduardo de Menezes Hospital, Funda&#xe7;&#xe3;o Hospitalar do Estado de Minas Gerais, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neto</LastName><ForeName>Cirilo Jos&#xe9; Ferreira</ForeName><Initials>CJF</Initials><AffiliationInfo><Affiliation>Infectious Disease Division, Eduardo de Menezes Hospital, Funda&#xe7;&#xe3;o Hospitalar do Estado de Minas Gerais, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Almeida Milagres</LastName><ForeName>Ana Carolina</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Infectious Disease Division, Eduardo de Menezes Hospital, Funda&#xe7;&#xe3;o Hospitalar do Estado de Minas Gerais, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>Tatiane Cristina Caldeira</ForeName><Initials>TCC</Initials><AffiliationInfo><Affiliation>Critical Care Unit, Eduardo de Menezes Hospital, Funda&#xe7;&#xe3;o Hospitalar do Estado de Minas Gerais, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>T&#xe1;ssia Lopardi</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Infectious Disease Division, Eduardo de Menezes Hospital, Funda&#xe7;&#xe3;o Hospitalar do Estado de Minas Gerais, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Souza</LastName><ForeName>Renan Pedra</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Integrative Biology Laboratory, Genetics, Ecology and Evolution Department, Biological Science Institute, Federal University of Minas Gerais, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>Israel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Ren&#xe9; Rachou Institute - Fiocruz Minas, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004408" MajorTopicYN="N">Dysgeusia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Brazil</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Dysgeusia</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>31</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35908724</ArticleId><ArticleId IdType="pmc">PMC9330427</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2022.07.063</ArticleId><ArticleId IdType="pii">S1201-9712(22)00458-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akbarialiabad H, Taghrir MH, Abdollahi A, Ghahramani N, Kumar M, Paydar S, et al. Long COVID, a comprehensive systematic scoping review. Infection. 2021;49:1163&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8317481</ArticleId><ArticleId IdType="pubmed">34319569</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021;76:399&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Munro M. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/3march2022, 2022 (accessed xx Month yyyy).</Citation></Reference><Reference><Citation>Bonif&#xe1;cio LP, Csizmar VNF, Barbosa-J&#xfa;nior F, Pereira APS, Koenigkam-Santos M, Wada DT, et al. Long-term symptoms among COVID-19 survivors in prospective cohort study. Brazil. Emerg Infect Dis. 2022;28:730&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8888217</ArticleId><ArticleId IdType="pubmed">35133956</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021;27:258&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534895</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Interim guidance on evaluating and caring for patients with post-COVID conditions. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-index.html, 2021 (accessed 6 April 2022).</Citation></Reference><Reference><Citation>Chevinsky JR, Tao G, Lavery AM, Kukielka EA, Click ES, Malec D, et al. Late conditions diagnosed 1-4 months following an initial coronavirus disease 2019 (COVID-19) encounter: a matched-cohort study using inpatient and outpatient administrative data-United States, 1 March-30 June 2020. Clin Infect Dis. 2021;73:S5&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135331</ArticleId><ArticleId IdType="pubmed">33909072</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Cruz RF, Waller MD, Perrin F, Periselneris J, Norton S, Smith LJ, et al. Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia. ERJ Open Res. 2021;7:00655&#x2013;02020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7585700</ArticleId><ArticleId IdType="pubmed">33575312</ArticleId></ArticleIdList></Reference><Reference><Citation>EuroQol. EQ-5D. https://euroqol.org/eq-5d-instruments/eq-5d-3l-about/, 2022 (accessed 9 April 2022).</Citation></Reference><Reference><Citation>Fumagalli C, Zocchi C, Tassetti L, Silverii MV, Amato C, Livi L, et al. Factors associated with persistence of symptoms 1 year after COVID-19: a longitudinal, prospective phone-based interview follow-up cohort study. Eur J Intern Med. 2022;97:36&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648678</ArticleId><ArticleId IdType="pubmed">34903448</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6:00542&#x2013;02020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26:1017&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal FM, Lam K, Sounderajah V, Clarke JM, Ashrafian H, Darzi A. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. EClinicalmedicine. 2021;36</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8141371</ArticleId><ArticleId IdType="pubmed">34036253</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs LG, Gourna Paleoudis E, Lesky-Di Bari D, Nyirenda T, Friedman T, Gupta A, Rasouli L, Zetkulic M, Balani B, Ogedegbe C, Bawa H, Berrol L, Qureshi N, Aschner JL. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLoS ONE. 2020;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7732078</ArticleId><ArticleId IdType="pubmed">33306721</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson KB, Rao M, Bonilla H, Subramanian A, Hack I, Madrigal M, et al. Patients with uncomplicated coronavirus disease 2019 (COVID-19) have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic. Clin Infect Dis. 2021;73:e826&#x2013;e829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7929039</ArticleId><ArticleId IdType="pubmed">33624010</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings G, Monaghan A, Xue F, Mockler D, Romero-Ortu&#xf1;o R. A systematic review of persistent symptoms and residual abnormal functioning following acute COVID-19: ongoing symptomatic phase vs post-COVID-19 syndrome. J Clin Med. 2021;10:5913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8708187</ArticleId><ArticleId IdType="pubmed">34945213</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoud MM, Abuohashish HM, Khairy DA, Bugshan AS, Khan AM, Moothedath MM. Pathogenesis of dysgeusia in COVID-19 patients: a scoping review. Eur Rev Med Pharmacol Sci. 2021;25:1114&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">33577069</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-a systematic review and meta-analysis. J Med Virol. 2022;94:253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76:396&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Salamanna F, Veronesi F, Martini L, Landini MP, Fini M. Post-COVID-19 syndrome: the persistent symptoms at the post-viral stage of the disease. a systematic review of the current data. Front Med (Lausanne) 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8129035</ArticleId><ArticleId IdType="pubmed">34017846</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Taboada M, Moreno E, Cari&#xf1;ena A, Rey T, Pita-Romero R, Leal S, et al. Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients. Br J Anaesth. 2021;126:e110&#x2013;e113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833644</ArticleId><ArticleId IdType="pubmed">33413976</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int, 2022 (accessed 17 July 2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>